Olanzapine-induced oculogyric crisis [1]

Journal of Clinical Psychopharmacology

Volumn 26, Issue 4, 2006, Pages 431-

  Rosenhagen, Marcus C ^a   Schmidt, Ulrike ^a   Winkelmann, Juliane ^a   Ebinger, Martin ^a   Knetsch, Iris ^b   Weber, Frank ^a  

^a MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

^b Klinikum Schwabing   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; BIPERIDEN; HALOPERIDOL; LITHIUM; OLANZAPINE; PAROXETINE; ZIPRASIDONE;

ADULT; CASE REPORT; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; FEMALE; GENERALIZED ANXIETY DISORDER; HUMAN; LETTER; NEUROTOXICITY; OCULOGYRIC CRISIS; PRIORITY JOURNAL;

ADULT; ANTIPSYCHOTIC AGENTS; ANXIETY DISORDERS; BENZODIAZEPINES; FEMALE; HUMANS; LITHIUM; OCULAR MOTILITY DISORDERS;

EID: 33746923029     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.jcp.0000227351.44664.19     Document Type: Letter

References (11)

1. Ciudad A, Gutierrez M, Canaset F, et al. Safety and effectiveness of olanzapine in monotherapy: a multivariate analysis of a naturalistic study. Prog Neuropsychopharmacol Biol Psychiatry. 2005;29(6):944-951.
2. Ramos AE, Shytle RD, Silver AA, et al. Ziprasidone-induced oculogyric crisis. J Am Acad Child Adolesc Psychiatry. 2003;42:1013-1014.
3. Frauenfelder FW, Fraunfelder FT. Adverse ocular drug reaction recently identified by the National Registry of Drug-Induced Ocular Side Effects. American Academy of Ophthalmology Annual Meeting; November 15-18, 2003; Anaheim, CA.
4. Engel J, Berggren U. Effects of lithium on behavior and central monoamines. Acta Psychiatr Scand Suppl. 1980;280:133-143.
5. Dorevitch A. Neuroleptics as causes of oculogyric crisis. Arch Neurol. 1984;41:15-16.
6. Sandyk R. Oculogyric crisis induced by lithium carbonate. Eur Neurol. 1984;23:92-94.
7. Emilien G, Maloteaux JM. Lithium neurotoxicity at low therapeutic doses. Hypotheses for causes and mechanism of action following a retrospective analysis of published case reports. Acta Neurol Belg. 1996;96:281-293.
8. Normann C, Brandt C, Berger M, et al. Delirium and persistent dyskinesia induced by a lithium-neuroleptic interaction. Pharmacopsychiatry. 1998;31:201-204.
9. Berry N, Pradhan S, Sagar R, et al. Neuroleptic malignant syndrome in an adolescent receiving olanzapine-lithium combination therapy. Pharmacotherapy. 2003;23(2):255-259.
10. Bourgeois JA, Kahn DR. Neuroleptic malignant syndrome following administration of risperidone and lithium. J Clin Psychopharmacol. 2003;23(3):315-317.
11. Borovicka MC, Bond LC, Gaughan KM. Ziprasidone-and lithium-induced neuroleptic malignant syndrome.AnnPharmacother.2006;40(1):139-142.